Genetic predisposition of interleukin-6 (rs1800797) polymorphism in cervical cancer: A Meta-analysis

Abstract

Background: Cervical cancer is a significant health burden, especially in less developed countries with limited access to HPV vaccines and screening. Dysregulation of immune cells, interleukin-6 (IL-6), and proinflammatory mediators have been implicated in cancer progression. SNPs in the IL-6 gene are thought to influence cervical cancer. A meta-analysis investigated the relationship between the IL-6 rs1800797 polymorphism and cervical cancer risk.

Methods: We conducted data mining on the PubMed database to identify relevant studies meeting specific criteria, including genotype data for IL-6 rs1800797, publication between 2015 and 2023, and reporting covariate risk factors. The meta-analysis comprised six publications focusing on the polymorphism at rs1800797 in IL-6 associated with cervical cancer.

Results: None of the five genetic models studied proved a significant link between the IL-6 rs1800797 polymorphism and cervical cancer risk. Because it included data from many ethnic groups, some racial groups may not experience the same consequences as others, based on this meta-analysis. The research revealed substantial heterogeneity. Egger's test and sensitivity analysis showed no evidence of publication bias.

Conclusion: Based on this comprehensive meta-analysis, we find no evidence that the IL-6 rs1800797 polymorphism contributes substantially to cervical cancer risk. However, further study is needed to investigate possible connections with additional IL-6 polymorphisms and the interplay between genetic and environmental variables in the development of cervical cancer. Identifying reliable tumor markers for cancer therapy remains an important area of investigation.